This Week In Diagnostics

IPSOGEN acquires rights for new cancer biomarkers IPSOGEN SA (Alternext: ALIPS), a majority-owned subsidiary of QIAGEN N.V. (Nasdaq: QGEN), has reported that it has acquired the worldwide exclusive rights to testing for mutations of the IDH1 and IDH2 genes for diagnostic purposes from Baltimore,...

Microvisk Limited Uses Same Technology as iPhone, ...

Written on Jan 23, 2012

Microvisk Limited is a UK-based medical technology company focused on developing medical testing devices based on micro electro medical sensors (MEMS) for the international healthcare market. The company is owned by private and venture capital investors including...

Cervilenz Inc. Reduces Premature Birth Risk with S...

Written on Jan 23, 2012

Since its commercial debut in 2011, the CerviLenz device, which is designed to help healthcare practitioners identify and manage pregnant women at high risk for premature birth has been shown to be nearly 100 percent effective in two recent clinical...

2B BlackBio is Focused on Reducing Mortality Rates...

Written on Jan 20, 2012

2B BlackBio is a privately held company based in Madrid, Spain focused on becoming a leader in personalized medicine and diagnostics. Founded in 2009, the company has recently completed a round of funding through the Madrid Network and the Spanish Ministry of Science...

Editor’s Note January 31, 2012

Written on Jan 4, 2012

The new year has brought with it some interesting developments in healthcare. In this issue, Tom Moore of Advaxis reports preliminary safety and survival data from a phase 2 trial in recurrent/refractory Cervical Cancer. Also, S.E.A. Medical secures $3M in series B...

AccuGenomics Seeks to Standardize Gene Expression ...

Written on Jan 4, 2012

Founded in 2010, AccuGenomics is a North Carolina-based, privately held genetics testing company focused on providing standardized gene expression tests to accurately diagnose, monitor and inform cancer treatments. The company has two tests in development to diagnose,...

March 8 – 9, 2012 Korea Investor Conference

Written on Dec 30, 2011

Shilla Hotel Seoul, Korea The 6th annual Citi Korea Investor Conference has evolved into one of the premier corporate access events in Korea. With over 70 corporates in attendance, investors from around the world can gather in one place for an indepth, first hand look...

recent comments

srebrenik shalom: we invested a lot of money in ADXS from the very begining an...
Alan S. Frankel: This conference call was excellent and I hope to follow Adva...
Copd untreated: What's COPD? COPD = continual Obstructive lung. Do you kn...
nicolette richards: I am 19 years old and I have trisomy 20 mosaicism and I was ...
eric: brett, thanks for this interview i just became a sharehold...
Jonathan Stuart: Pre-IPO funds are also run by MidasLP.com, GSV and several o...

recent from News This Week In Diagnostics

recent from Research ADVENTRX Pharmaceuticals Takes the Next Step In Approval of ANX-530

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they’ve been successful in sending their ANX-530 (Exelbine™) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug...

recent from Profiles Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues

The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product. Recent studies have indicated that the time to gain approval is dramatically different...

recent from Video June 23-24 OneMedForum New York

OneMedPlace Trans-Atlantic Conference on June 23rd-24th is a gathering of fast growing, emerging healthcare and life science companies in Europe and North America. Its sixth OneMedForum, and second in New York, OneMedPlace will focus on critical success factors for building companies on both sides of the...